Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Citi
US Department of Justice
Healthtrust
Daiichi Sankyo
Mallinckrodt
Accenture

Generated: August 20, 2019

DrugPatentWatch Database Preview

Litigation Details for Novartis Pharmaceuticals Corp. v. Watson Pharmaceuticals, Inc. (S.D.N.Y. 2005)

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Novartis Pharmaceuticals Corp. v. Watson Pharmaceuticals, Inc. (S.D.N.Y. 2005)

Docket ➤ Sign Up Date Filed 2005-02-18
Court District Court, S.D. New York Date Terminated 2008-02-29
Cause 35:145 Civil Action to Obtain Patent Assigned To Harold Baer Jr.
Jury Demand None Referred To
Parties NOVARTIS AG; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.; NOVARTIS INTERNATIONAL PHARMACEUTICAL, LTD.; NOVARTIS PHARMA AG; NOVARTIS PHARMACEUTICALS CORP.; NOVARTIS PHARMACEUTICALS CORPORATION; PROTERRA AG; WATSON LABORATORIES INC.; WATSON LABORATORIES, INC.; WATSON PHARMACEUTICALS, INC.
Patents 4,948,807
Attorneys Barry S. White; Diego Scambia; Edward Anthony Kmett , Jr.; Filko Prugo; James Kevin Stronski; Kimberly McGraw; Leonard J. Santisi; Michael K. O'Neill; Robert Louis Baechtold
Firms Fitzpatrick, Cella, Harper & Scinto; Fitzpatrick, Cella, Harper & Scinto(NYC); Frommer Lawrence & Haug; Frommer, Lawrence & Haug, L.L.P.
Link to Docket External link to docket
Small Molecule Drugs cited in Novartis Pharmaceuticals Corp. v. Watson Pharmaceuticals, Inc.
The small molecule drug covered by the patent cited in this case is ➤ Sign Up .

Details for Novartis Pharmaceuticals Corp. v. Watson Pharmaceuticals, Inc. (S.D.N.Y. 2005)

Date Filed Document No. Description Snippet Link To Document
2005-05-25 11 807 patent. THIRD DEFENSE INVALIDITY OF UNITED STATES PATENT NO. 4,948,807 34. The ‘807 patent and … admits only that United States Patent No. 4,948,807 (“the ‘807 patent”) on its face identifies Plaintiff…OF UNITED STATES PATENT NO. 4,948,807 DUE TO INEQUITABLE CONDUCT 35. The ‘807 patent is unenforceable…ORDER OF DELETION OF UNITED STATES PATENT NO. 4,948,807 FROM PATENT INFORMATION FOR NOVARTIS PHARMACEUTICAL…of 16 69. Because United States Patent No. 4,948,807 (“the ‘807 patent”) does not claim the drug for which External link to document
2005-05-26 12 807 patent. THIRD DEFENSE INVALIDITY OF UNITED STATES PATENT NO. 4,948,807 34. The ‘807 patent and … admits only that United States Patent No. 4,948,807 (“the ‘807 patent”) on its face identifies Plaintiff…OF UNITED STATES PATENT NO. 4,948,807 DUE TO INEQUITABLE CONDUCT 35. The ‘807 patent is unenforceable…ORDER OF DELETION OF UNITED STATES PATENT NO. 4,948,807 FROM PATENT INFORMATION FOR NOVARTIS PHARMACEUTICAL…of 15 69. Because United States Patent No. 4,948,807 (“the ‘807 patent”) does not claim the drug for which External link to document
2007-09-19 28 Support of Their Proposed Construction of U.S. Patent 4,948,807. Document filed by Novartis Pharma AG, Novartis…2005 29 February 2008 1:05-cv-02234-HB Patent None District Court, S.D. New External link to document
2005-04-25 3 Book, U.S. Patent Nos. 4,948,807 (“the ‘807 patent”) and 5,602,176 (“the ‘176 patent”). (Taavola…324 F.3d at 1325-26. “Method-of-use patents,” that is, patents that cover a drug’s specific uses, may… 354 F.3d at 879. The patent holder then has 45 days in which to file a patent- infringement suit. …the ‘807 patent and 3 claim 5 of the ‘176 patent. (Plaintiffs…certification pertaining only to the ‘176 patent. (Amended Complaint for Patent Infringement against Sun, attached External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Fuji
Accenture
Argus Health
Healthtrust
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.